Aurobindo Pharma Buyback 2026 Record Date, Price & Ratio Details

Aurobindo Pharma Buyback 2026 details: The Aurobindo Pharma Buyback open date is 2026. Aurobindo Pharma Buyback record date is April 17, 2026. The investor should buy the Aurobindo Pharma Buyback shares before the record date to get eligibility for the buyback.

Aurobindo Pharma Buyback 2026

Aurobindo Pharma’s buyback of ₹800 crores approved by the board of directors at the meeting was held on March 31, 2026. Aurobindo Pharma Buyback will be done via the Tender Offer route through the stock exchange mechanism. The board of directors of the company approved the buyback by the Company of its fully paid-up equity shares having a face value of ₹1 each equity share at a price of ₹1,475 per Equity Share and for an aggregate amount not exceeding ₹800 crores from the shareholders. Check out Aurobindo Pharma Buyback 2026 details below:


Aurobindo Pharma Buyback About us

To be updated soon

Aurobindo Pharma Buyback History

  • N/A

Aurobindo Pharma Buyback 2026 Dates

Buyback Meeting Date:March 31, 2026
Buyback Announcement Date:2026
Buyback Record Date:April 17, 2026
Last Date to Buy Shares:2026
Buyback Open Date:2026
Buyback Close Date:2026
Finalization of Buyback Acceptance:2026

Aurobindo Pharma Buyback 2026 Offer Details

Aurobindo Pharma Buyback ofĀ 54,23,728 equity shares at a price of ₹1,475 per equity share. The buyback offers not to exceed ₹800 crores of the total buyback offer size.

Offer Amount:₹800 Crores
Number of Shares:54,23,728 Equity Shares
Face Value:₹1 per equity share
Buyback Price:₹1,475 per equity share
Listing:BSE, NSE
Buyback Type:Tender Offer
Letter of Offer:Click Here

Aurobindo Pharma Buyback 2026 Acceptance Ratio

The investor should buy around 136 shares at a current market price of ₹1,340.20 (as of date). The calculation will be ₹2,00,000 / ₹1,475 buyback price = 136 shares.

Acceptance RatioInvestmentShares BuybackProfit
33%₹1,82,26745₹60,148
50%₹1,82,26768₹91,134
75%₹1,82,267102₹1,36,700
100%₹1,82,267136₹1,81,722

Aurobindo Pharma Financial Report

₹ in Crores
YearRevenueExpensePAT
2023₹13,226.04₹11,611.69₹1,230.41
2024₹11,261.70₹8,858.78₹1,954.14
2025₹11,261.42₹8,902.97₹1,746.79

How to Participate in Aurobindo Pharma Buyback 2026

The investors are eligible for the buyback scheme who have Aurobindo Pharma Buyback shares in their Demat Account as the Record Date. Eligible Share Holders can participate in the Aurobindo Pharma Buyback 2026 scheme as per the opening form by selling their shares. The payment will be given as per the Aurobindo Pharma Buyback accepted shares by the company under the Aurobindo Pharma Buyback scheme.

Aurobindo Pharma Buyback 2026 Registrar

To be updated soon

Aurobindo Pharma Buyback 2026 Lead Managers

  • To be updated soon

Aurobindo Pharma Company Address

Aurobindo Pharma Limited
Plot No. 2, Maithrivihar,
Ameerpet,
Hyderabad – 500 038,
Telangana, India.
Phone: +91 40 2373 6370/ 2374 7340
E-Mail: info@aurobindo.com
Website: https://www.aurobindo.com/

Aurobindo Pharma Buyback 2026 FAQs


When is Aurobindo Pharma Buyback 2026 Record Date?

Aurobindo Pharma Buyback 2026 record date is April 17, 2026.

When is Aurobindo Pharma Buyback 2026 Open Date?

Aurobindo Pharma Buyback 2026 open date is 2026.

What is Aurobindo Pharma Buyback 2026 Price?

The company has fixed the price at ₹1,475 per share.

How to apply for Aurobindo Pharma Buyback 2026?

As per the record date you need to have Aurobindo Pharma Buyback shares in your Demat Account. You can participate in buyback after having the stock in your Account.

Table of Contents

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.

Disclaimer: This content is provided strictly for educational and informational purposes. The securities or investments mentioned are not to be considered as investment advice or recommendations. The Investors are advised to do their own research or connect with a financial advisor before making any investment decisions.

Leave a Reply

Your email address will not be published. Required fields are marked *